Weibin Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weibin Wu has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Hongyu Guan
Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3 shared publications - Kai Zhang
Department of Cardiothoracic Surgery, Third Affiliated Hospital of Sun Yat-sen University, 2693 Kaichuang Avenue, Huangpu District, Guangzhou, 510000, China, 86 13922192727, 86 82179042
3 shared publications Jiannan Xu
2 shared publications- Junchao Cai
Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
2 shared publications Libao Liu
2 shared publications- Tianyu Tao
Cancer Research Institute School of Basic Medical Sciences Southern Medical University Guangzhou China
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (9) , 722
Efficacy and safety of the RC120 navigation system for the computed tomography-guided localization of pulmonary ground-glass nodules: a prospective study with historical controls
Background: Conventional computed tomography (CT)–-guided pulmonary nodule localization often has unsatisfactory precision and efficiency. The new RC120 navigation system (Shanghai Simple Touch Technology Co., Ltd.) is designed to streamline this process. This study aimed to evaluate the efficacy and safety of the RC120 system for the preoperative localization of ground-glass nodules (GGNs) by comparing a prospectively enrolled cohort operated by a novice to a historical control cohort operated by experts. Methods: This single-center study included a prospective cohort of 39 patients scheduled to undergo RC120-assisted localization by a single surgeon with no prior experience in CT-guided percutaneous interventions between July 2024 and January 2025. This group was compared to a retrospective control cohort of 138 patients who underwent conventional free-hand localization by two experienced surgeons between November 2021 and October 2023. The primary endpoint was the overall procedural success rate, defined as successful anchor deployment within 10 mm of the target nodule’s border. Key secondary endpoints included localization time, radiation dose, number of needle adjustments, and safety. Results: The baseline characteristics were well-balanced between the groups. Despite the RC120 group having a numerically lower success rate compared to the control group, the difference did not reach statistical significance (82.1% vs. 92.8%; P=0.062), with all RC120 anchor deployments remaining clinically adequate for surgical guidance. Although the procedures in the RC120 group were performed by a novice, there were significant improvements in key efficiency metrics as compared to the control group: the median localization time was shorter (15.0 min vs. 20.5 min; Pvs. 2; Pvs. 1091.4 mGy·cm; P=0.003). In terms of safety, the RC120 group had a significantly lower rate of hemothorax (2.6% vs. 21.0%; P=0.006). Learning curve analysis of the novice operator showed no significant correlation between case sequence and procedure time (rs=0.072; P=0.66), indicating a rapid acquisition of proficiency. Conclusions: In this preliminary study, use of the RC120 navigation system by a novice operator appeared feasible for GGN localization and was associated with enhanced procedural efficiency and reduced hemorrhagic complications as compared to historical free-hand techniques. The lack of a significant correlation between procedure time and case sequence suggests a minimal learning phase. These findings should be validated in future large-scale, randomized controlled trials.
- 1 September 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (9) , 722
Open AccessEfficacy and safety of the RC120 navigation system for the computed tomography-guided localization of pulmonary ground-glass nodules: a prospective study with historical controls
Background: Conventional computed tomography (CT)–-guided pulmonary nodule localization often has unsatisfactory precision and efficiency. The new RC120 navigation system (Shanghai Simple Touch Technology Co., Ltd.) is designed to streamline this process. This study aimed to evaluate the efficacy and safety of the RC120 system for the preoperative localization of ground-glass nodules (GGNs) by comparing a prospectively enrolled cohort operated by a novice to a historical control cohort operated by experts. Methods: This single-center study included a prospective cohort of 39 patients scheduled to undergo RC120-assisted localization by a single surgeon with no prior experience in CT-guided percutaneous interventions between July 2024 and January 2025. This group was compared to a retrospective control cohort of 138 patients who underwent conventional free-hand localization by two experienced surgeons between November 2021 and October 2023. The primary endpoint was the overall procedural success rate, defined as successful anchor deployment within 10 mm of the target nodule’s border. Key secondary endpoints included localization time, radiation dose, number of needle adjustments, and safety. Results: The baseline characteristics were well-balanced between the groups. Despite the RC120 group having a numerically lower success rate compared to the control group, the difference did not reach statistical significance (82.1% vs. 92.8%; P=0.062), with all RC120 anchor deployments remaining clinically adequate for surgical guidance. Although the procedures in the RC120 group were performed by a novice, there were significant improvements in key efficiency metrics as compared to the control group: the median localization time was shorter (15.0 min vs. 20.5 min; Pvs. 2; Pvs. 1091.4 mGy·cm; P=0.003). In terms of safety, the RC120 group had a significantly lower rate of hemothorax (2.6% vs. 21.0%; P=0.006). Learning curve analysis of the novice operator showed no significant correlation between case sequence and procedure time (rs=0.072; P=0.66), indicating a rapid acquisition of proficiency. Conclusions: In this preliminary study, use of the RC120 navigation system by a novice operator appeared feasible for GGN localization and was associated with enhanced procedural efficiency and reduced hemorrhagic complications as compared to historical free-hand techniques. The lack of a significant correlation between procedure time and case sequence suggests a minimal learning phase. These findings should be validated in future large-scale, randomized controlled trials.
- Top Cited Papers
- 6 March 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (4) , 797-811
The lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer
How cancer cells couple metabolic stress sensing to orchestrate specific survival programmes is a key question. Here we show a long non-coding RNA (lncRNA)-guided epitranscriptomic mechanism orchestrating metabolic adaptation by controlling the stability of master stress regulator ATF4. Glucose or glutamine deprivation induces endoplasmic reticulum stress via reactive oxygen species–NRF2-dependent transcription of the lncRNA DAMER. Following its demethylation and nuclear retention by the m6A-eraser ALKBH5, DAMER acts as a scaffold, guiding ALKBH5 to demethylate and stabilize ATF4 mRNA through specific base-pairing. This provides an alternative post-transcriptional pathway for ATF4 upregulation, rewiring asparagine metabolism to promote cancer cell survival under stress. Furthermore, we identified the US FDA-approved drug elbasvir as a potent inhibitor of the DAMER–ALKBH5 interaction. Elbasvir dismantles this adaptive programme, targeting tumour asparagine dependency and exhibiting potent antitumour effects in preclinical models. Our findings reveal a paradigm for lncRNA-guided RNA demethylation that solves a target specificity enigma and offers a strategy targeting metabolic adaptation in cancer.
- 6 March 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (4) , 797-811
Top Cited PapersThe lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer
How cancer cells couple metabolic stress sensing to orchestrate specific survival programmes is a key question. Here we show a long non-coding RNA (lncRNA)-guided epitranscriptomic mechanism orchestrating metabolic adaptation by controlling the stability of master stress regulator ATF4. Glucose or glutamine deprivation induces endoplasmic reticulum stress via reactive oxygen species–NRF2-dependent transcription of the lncRNA DAMER. Following its demethylation and nuclear retention by the m6A-eraser ALKBH5, DAMER acts as a scaffold, guiding ALKBH5 to demethylate and stabilize ATF4 mRNA through specific base-pairing. This provides an alternative post-transcriptional pathway for ATF4 upregulation, rewiring asparagine metabolism to promote cancer cell survival under stress. Furthermore, we identified the US FDA-approved drug elbasvir as a potent inhibitor of the DAMER–ALKBH5 interaction. Elbasvir dismantles this adaptive programme, targeting tumour asparagine dependency and exhibiting potent antitumour effects in preclinical models. Our findings reveal a paradigm for lncRNA-guided RNA demethylation that solves a target specificity enigma and offers a strategy targeting metabolic adaptation in cancer.
- Open Access
- 5 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35
Targeting chemokine-driven metastasis in non-small cell lung cancer: Development and evaluation of chemokine nanosponges for therapy
- 5 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35
Open AccessTargeting chemokine-driven metastasis in non-small cell lung cancer: Development and evaluation of chemokine nanosponges for therapy
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 8796-8808
NUF2 promotes the malignant development of lung adenocarcinoma through the mTORC1 signaling pathway via binding to BUB1B
Background: Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality globally. Despite advances in therapy, treatment resistance and poor prognosis necessitate novel therapeutic targets. Nuclear filament-containing protein 2 (NUF2), a component of the nuclear division cycle 80 (NDC80) complex, is implicated in oncogenesis, but its role and molecular mechanisms in LUAD are poorly understood. The aim of this study is to explore the role of NUF2 in malignant development of LUAD in vivo. Methods: Bioinformatics analysis using Gene Expression Profiling Interactive Analysis (GEPIA) and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) databases evaluated NUF2/BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) expression and interactions. Functional assays (cell counting kit-8, colony formation, apoptosis, wound healing, transwell) and molecular techniques (real-time quantitative polymerase chain reaction, Western blot, co-immunoprecipitation) were performed in LUAD cell lines (A549, PC-9, NCI-H1975). The binding of NUF2 and BUB1B was verified by co-immunoprecipitation assay. An in vivo LUAD model was established with nude mice and the mTORC1 (mechanistic target of rapamycin complex 1) pathway was examined by Western blot. Results: NUF2 was significantly upregulated in LUAD tissues and correlated with advanced stage and poor survival (PIn vivo, NUF2 silencing inhibited tumor growth, which was reversed by BUB1B overexpression (PConclusions: NUF2 drives LUAD progression via BUB1B-mediated mTORC1 activation. Targeting the NUF2/BUB1B axis may offer a promising therapeutic strategy to mitigate LUAD malignancy. These findings provide critical insights into the molecular underpinnings of LUAD and highlight potential pathways for clinical intervention.
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 8796-8808
Open AccessNUF2 promotes the malignant development of lung adenocarcinoma through the mTORC1 signaling pathway via binding to BUB1B
Background: Lung adenocarcinoma (LUAD), the most prevalent subtype of non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality globally. Despite advances in therapy, treatment resistance and poor prognosis necessitate novel therapeutic targets. Nuclear filament-containing protein 2 (NUF2), a component of the nuclear division cycle 80 (NDC80) complex, is implicated in oncogenesis, but its role and molecular mechanisms in LUAD are poorly understood. The aim of this study is to explore the role of NUF2 in malignant development of LUAD in vivo. Methods: Bioinformatics analysis using Gene Expression Profiling Interactive Analysis (GEPIA) and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) databases evaluated NUF2/BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B) expression and interactions. Functional assays (cell counting kit-8, colony formation, apoptosis, wound healing, transwell) and molecular techniques (real-time quantitative polymerase chain reaction, Western blot, co-immunoprecipitation) were performed in LUAD cell lines (A549, PC-9, NCI-H1975). The binding of NUF2 and BUB1B was verified by co-immunoprecipitation assay. An in vivo LUAD model was established with nude mice and the mTORC1 (mechanistic target of rapamycin complex 1) pathway was examined by Western blot. Results: NUF2 was significantly upregulated in LUAD tissues and correlated with advanced stage and poor survival (PIn vivo, NUF2 silencing inhibited tumor growth, which was reversed by BUB1B overexpression (PConclusions: NUF2 drives LUAD progression via BUB1B-mediated mTORC1 activation. Targeting the NUF2/BUB1B axis may offer a promising therapeutic strategy to mitigate LUAD malignancy. These findings provide critical insights into the molecular underpinnings of LUAD and highlight potential pathways for clinical intervention.
- Open Access
- 14 August 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e73941
Application of Large Language Models in Complex Clinical Cases: Cross-Sectional Evaluation Study
Background: Large language models (LLMs) have made significant advancements in natural language processing (NLP) and are gradually showing potential for application in the medical field. However, LLMs still face challenges in medicine. Objective: This study aims to evaluate the efficiency, accuracy, and cost of LLMs in handling complex medical cases and to assess their potential and applicability as tools for clinical decision support. Methods: We selected cases from the database of the Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University (2021‐2024), and conducted a multidimensional preliminary evaluation of the latest LLMs in clinical decision-making for complex cases. The evaluation included measuring the time taken for the LLMs to generate decision recommendations, Likert scores, and calculating decision costs to assess the execution efficiency, accuracy, and cost-effectiveness of the models. Results: A total of 80 complex cases were included in this study, and the performance of multiple LLMs in clinical decision-making was evaluated. Experts required 33.60 minutes on average (95% CI 32.57‐34.63), far longer than any LLM. GPTo1 (0.71, 95% CI 0.67‐0.74), GPT4o (0.88, 95% CI 0.83‐0.92), and Deepseek (0.94, 95% CI 0.90‐0.96) all finished under a minute without statistical differences. Although Kimi, Gemini, LLaMa3-8B, and LLaMa3-70B took 1.02‐3.20 minutes, they were still faster than experts. In terms of decision accuracy, Deepseek-R1 had the highest accuracy (mean Likert score=4.19), with no significant difference compared to GPTo1 (P=.699), and both performed significantly better than GPT4o, Kimi, Gemini, LLaMa3-70B, and LLaMa3-8B (P<.001). Deepseek-R1 and GPTo1 demonstrated the lowest hallucination rates—6/80 (8%) and 5/80 (6%), respectively—significantly outperforming GPT-4o (7/80, 9%), Kimi (10/80, 12%), and the Gemini and LLaMa3 models, which exhibited substantially higher rates ranging from 13/80 (16%) to 25/80 (31%). Regarding decision costs, all LLMs showed significantly lower costs than the Multidisciplinary Team, with open-source models such as Deepseek-R1 offering a zero direct cost advantage. Conclusions: GPTo1 and Deepseek-R1 show strong clinical potential, boosting efficiency, maintaining accuracy, and reducing costs. GPT4o and Kimi performed moderately, indicating suitability for broader clinical tasks. Further research is needed to validate LLaMa3 series and Gemini in clinical decision.
- 14 August 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e73941
Open AccessApplication of Large Language Models in Complex Clinical Cases: Cross-Sectional Evaluation Study
Background: Large language models (LLMs) have made significant advancements in natural language processing (NLP) and are gradually showing potential for application in the medical field. However, LLMs still face challenges in medicine. Objective: This study aims to evaluate the efficiency, accuracy, and cost of LLMs in handling complex medical cases and to assess their potential and applicability as tools for clinical decision support. Methods: We selected cases from the database of the Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University (2021‐2024), and conducted a multidimensional preliminary evaluation of the latest LLMs in clinical decision-making for complex cases. The evaluation included measuring the time taken for the LLMs to generate decision recommendations, Likert scores, and calculating decision costs to assess the execution efficiency, accuracy, and cost-effectiveness of the models. Results: A total of 80 complex cases were included in this study, and the performance of multiple LLMs in clinical decision-making was evaluated. Experts required 33.60 minutes on average (95% CI 32.57‐34.63), far longer than any LLM. GPTo1 (0.71, 95% CI 0.67‐0.74), GPT4o (0.88, 95% CI 0.83‐0.92), and Deepseek (0.94, 95% CI 0.90‐0.96) all finished under a minute without statistical differences. Although Kimi, Gemini, LLaMa3-8B, and LLaMa3-70B took 1.02‐3.20 minutes, they were still faster than experts. In terms of decision accuracy, Deepseek-R1 had the highest accuracy (mean Likert score=4.19), with no significant difference compared to GPTo1 (P=.699), and both performed significantly better than GPT4o, Kimi, Gemini, LLaMa3-70B, and LLaMa3-8B (P<.001). Deepseek-R1 and GPTo1 demonstrated the lowest hallucination rates—6/80 (8%) and 5/80 (6%), respectively—significantly outperforming GPT-4o (7/80, 9%), Kimi (10/80, 12%), and the Gemini and LLaMa3 models, which exhibited substantially higher rates ranging from 13/80 (16%) to 25/80 (31%). Regarding decision costs, all LLMs showed significantly lower costs than the Multidisciplinary Team, with open-source models such as Deepseek-R1 offering a zero direct cost advantage. Conclusions: GPTo1 and Deepseek-R1 show strong clinical potential, boosting efficiency, maintaining accuracy, and reducing costs. GPT4o and Kimi performed moderately, indicating suitability for broader clinical tasks. Further research is needed to validate LLaMa3 series and Gemini in clinical decision.
- Open Access
- 20 February 2025
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 19
The Clinical Impact of Heart Failure on the Postoperative Outcomes for Lung Cancer Patients Undergoing Lobectomy and Sublobar Resection by Video-Assisted Thoracic Surgery: A Propensity Score-Matched Analysis of 2016-2020 HCUP-NIS Data
Background: The clinical impact of heart failure (HF) on postoperative outcomes following video-assisted thoracic surgery (VATS) for lung cancer resection remains controversial. This study aimed to assess patient and hospital characteristics related to the type of surgery, as well as the independent impact of HF on surgical outcomes. Methods: We conducted a retrospective analysis using data from the National Inpatient Sample database. A total of 20 693 patients aged 18 years or older, diagnosed with lung cancer, and undergoing lobectomy or sublobar resection via VATS between 2016 and 2020 were included. Patients were stratified based on the presence of HF. The HF-present cohorts were matched to HF-absent controls using a 1:2 nearest-neighbor propensity score-matching (PSM) analysis. The matched cohorts were then compared across several endpoints, including mortality, length of stay (LOS), hospitalization costs, and postoperative complications. Results: After PSM, the study included 1781 patients who underwent lobectomy and 1157 who underwent sublobar resection, with 594 and 386 patients, respectively, having concurrent HF. In both the lobectomy and sublobar resection groups, patients with HF demonstrated significantly higher in-hospital mortality rates ( P < .001), longer LOS ( P < .001), increased total hospital charges ( P < .001), and a greater risk for overall postoperative complications ( P < .001). Conclusions: Among patients with lung cancer undergoing VATS, the presence of HF is associated with an increased risk of postoperative complications. This finding underscores the necessity for enhanced monitoring and care for patients with HF should be treated during the postoperative recovery phase.
- 20 February 2025
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 19
Open AccessThe Clinical Impact of Heart Failure on the Postoperative Outcomes for Lung Cancer Patients Undergoing Lobectomy and Sublobar Resection by Video-Assisted Thoracic Surgery: A Propensity Score-Matched Analysis of 2016-2020 HCUP-NIS Data
Background: The clinical impact of heart failure (HF) on postoperative outcomes following video-assisted thoracic surgery (VATS) for lung cancer resection remains controversial. This study aimed to assess patient and hospital characteristics related to the type of surgery, as well as the independent impact of HF on surgical outcomes. Methods: We conducted a retrospective analysis using data from the National Inpatient Sample database. A total of 20 693 patients aged 18 years or older, diagnosed with lung cancer, and undergoing lobectomy or sublobar resection via VATS between 2016 and 2020 were included. Patients were stratified based on the presence of HF. The HF-present cohorts were matched to HF-absent controls using a 1:2 nearest-neighbor propensity score-matching (PSM) analysis. The matched cohorts were then compared across several endpoints, including mortality, length of stay (LOS), hospitalization costs, and postoperative complications. Results: After PSM, the study included 1781 patients who underwent lobectomy and 1157 who underwent sublobar resection, with 594 and 386 patients, respectively, having concurrent HF. In both the lobectomy and sublobar resection groups, patients with HF demonstrated significantly higher in-hospital mortality rates ( P < .001), longer LOS ( P < .001), increased total hospital charges ( P < .001), and a greater risk for overall postoperative complications ( P < .001). Conclusions: Among patients with lung cancer undergoing VATS, the presence of HF is associated with an increased risk of postoperative complications. This finding underscores the necessity for enhanced monitoring and care for patients with HF should be treated during the postoperative recovery phase.
- Open Access
LincRNA01703 Facilitates CD81+ Exosome Secretion to Inhibit Lung Adenocarcinoma Metastasis via the Rab27a/SYTL1/CD81 Complex
Metastasis, a major cause of cancer-related mortality worldwide, frequently occurs early in the diagnosis of lung adenocarcinoma (LUAD). However, the precise molecular mechanisms governing the aggressive metastatic behavior of LUAD remain incompletely understood. In this study, we present compelling evidence indicating that the long noncoding RNA linc01703 is significantly downregulated in metastatic lung cancer cells. Intriguingly, in vivo experiments revealed that Linc01703 exerted a profound inhibitory effect on lung cancer metastasis without discernible impact on the in vitro proliferation or invasion capacities of LUAD cells. Mechanistically, Linc01703 enhanced the interaction between Rab27a, SYTL1, and CD81, consequently promoting the secretion of CD81+ exosomes. These exosomes, in turn, suppressed the infiltration of immune cells within the tumor microenvironment, thereby impeding LUAD metastasis. Importantly, our analysis of lung cancer tissues revealed a correlation between reduced CD81 expression and an unfavorable patient prognosis. Collectively, our findings suggest that Linc01703 functions as a metastasis suppressor by facilitating the secretion of CD81+ exosomes through the formation of the Rab27a/SYTL1/CD81 complex.
Open AccessLincRNA01703 Facilitates CD81+ Exosome Secretion to Inhibit Lung Adenocarcinoma Metastasis via the Rab27a/SYTL1/CD81 Complex
Metastasis, a major cause of cancer-related mortality worldwide, frequently occurs early in the diagnosis of lung adenocarcinoma (LUAD). However, the precise molecular mechanisms governing the aggressive metastatic behavior of LUAD remain incompletely understood. In this study, we present compelling evidence indicating that the long noncoding RNA linc01703 is significantly downregulated in metastatic lung cancer cells. Intriguingly, in vivo experiments revealed that Linc01703 exerted a profound inhibitory effect on lung cancer metastasis without discernible impact on the in vitro proliferation or invasion capacities of LUAD cells. Mechanistically, Linc01703 enhanced the interaction between Rab27a, SYTL1, and CD81, consequently promoting the secretion of CD81+ exosomes. These exosomes, in turn, suppressed the infiltration of immune cells within the tumor microenvironment, thereby impeding LUAD metastasis. Importantly, our analysis of lung cancer tissues revealed a correlation between reduced CD81 expression and an unfavorable patient prognosis. Collectively, our findings suggest that Linc01703 functions as a metastasis suppressor by facilitating the secretion of CD81+ exosomes through the formation of the Rab27a/SYTL1/CD81 complex.